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Objectives: Human Urinary Kallidinogenase (HUK) is a tissue kallikrein that plays
neuroprotective role in ischemic conditions via different mechanisms. Mild hypothermia
(MH) is another robust neuroprotectant that reduces mortality but does not profoundly
ameliorate the neurological outcome in hypoxic-ischemic encephalopathy (HIE) patients.
However, whether the combination of HUK and MH can be used as a promising
neuroprotective treatment in HIE is unknown.
Methods: One-hundred and forty-four adult Wistar rats were randomly divided into
five groups: Sham, HIE, HUK, MH and a combination of HUK and MH treatment. The
HIE rat model was established by right carotid dissection followed by hypoxia aspiration.
The survival curve was created within 7 days, and the neurological severity scores
(NSS) were assessed at days 0, 1, 3, and 7. Nissl staining, Terminal deoxynucleotidyl
transferase-mediated dUTP nick end-labeling (TUNEL), immunofluorescent staining and
western blotting were used to evaluate neuronal survival, apoptosis and necrosis, tight-
junction proteins Claudin-1 and Zonula occludens-1 (ZO-1), vascular endothelial growth
factor (VEGF), doublecortex (DCX), bradykinin receptor B1 (BDKRB1), BDKRB2 and
Ki67 staining.
Abbreviations: BBB, Blood-brain barrier; BDKRB1, Bradykinin receptor B1; BDKRB2, Bradykinin receptor B2; DCX,
Doublecortex; ELAM-1, selectin E; HIE, Hypoxic-ischemic encephalopathy; HUK, Human urinary kallidinogenase;
IL-1, Interleukin-1; IL-6, Interleukin-6; LOX-1, low-density lipoprotein receptor-1; MCP-1, Monocyte chemoattractant
protein 1; MH, Mild hypothermia; NF-κB, Nuclear Factor-κB; nNOS, nitric oxide synthase; OGD/R, Oxygen and glucose
deprivation-reoxygenation; TNF-α, Tumor necrosis factor-α; TUNEL, Terminal deoxynucleotidyl transferase-mediated
dUTP nick end-labeling; VEGF, Vascular endothelial growth factor; ZO-1, Zonula occludens-1.
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Results: The combined treatment rescued all HIE rats from death and had a best
survival curve compared to HIE. The Combination also reduced the NSS scores after
HIE at days 7, better than HUK or MH alone. The combination of HUK and MH
reserved more cells in Nissl staining and inhibited neuronal apoptosis and necrosis
as well as significantly attenuated HIE-induced decreases in claudin-1, ZO-1, cyclin
D1 and BDKRB1/B2 in comparison to HUK or MH treatment alone. Moreover, the
combined treatment increased the expression of VEGF and DCX as well as the number
of Ki67-labeled cells.
Conclusions: This study demonstrates that both HUK and MH are neuroprotective after
HIE insult; however, the combined therapy with HUK and MH enhanced the efficiency
and efficacy of either therapy alone in the treatment of HIE, at least partially by promoting
angiogenesis and regeneration and rescuing tight-junction loss. The combination of HUK
and MH seems to be a feasible and promising clinical strategy to alleviate cerebral injury
following HIE insult.
Highlights:
- The combination of HUK and MH distinctly reduces neurological
dysfunction in HIE rats.
- HUK enhances the neuroprotective effects of MH in HIE.
- MH attenuates tight-junction disruption, upregulates the BDKR B1/2, DCX
and cyclin D1.
- The combination of MH and HUK enhances the expressions of MH/HUK
mediated-BDKR B1/2, DCX, cyclin D1 and Ki67 positive cells.
Keywords: hypoxic-ischemic encephalopathy, neuroprotectant, human urinary kallidinogenase, mild hypothermia,
angiogenesis, regeneration
INTRODUCTION
Hypoxic-ischemic encephalopathy (HIE) is a quite common
and severe disorder in neonates, children and adults and is
also a leading cause of mortality and morbidity. The neuro-
pathogenesis of brain injury in patients with HIE remains largely
elusive. The molecular mechanisms may include brain-blood-
barrier (BBB) breakdown, tight junction and microvascular
disruptions, edema and cell death (Guardia Clausi et al.,
2016; Kossatz et al., 2016; Thornton et al., 2017). A better
understanding of the pathogenesis of HIE is needed, and it is
necessary to develop various novel and effective treatments for
HIE brain injury.
It has been documented that mild hypothermia (MH) is
effective in the treatment of HIE. The potential mechanisms of
MH may include the dramatic inhibition of autophagosomes
and lysosomes; reduction of the activity of neuronal nitric
oxide synthase (nNOS) and apoptotic caspase enzymes (Wood
et al., 2016); downregulated expression of lectin-like oxidized
low-density lipoprotein receptor-1 (LOX-1), tumor necrosis
factor-α (TNF-α) and oxidant species (Akamatsu et al., 2014);
and induction of cold-shock proteins and heat shock proteins
correlated with subsequent apoptosis (Lee et al., 2017). Clinically,
although therapeutic MH alleviates cell damages and results
in lower death rates in HIE (Mitra et al., 2017), the limited
efficacy of hypothermia is insufficient and only slightly improves
serious neurological impairments (Shankaran et al., 2012;
Manley et al., 2017). Therefore, it is necessary to find a
strategy to enhance the neuroprotective effects of MH in the
treatment of HIE. These facts also inspired us to explore
combined treatments of MH with certain neuroprotectants. In
our previous study, we screened a series of medicines that
might have synergistic effects or enhance the positive effects
of MH (34◦C for 4.5 h) on primary cortical neurons following
oxygen glucose deprived (OGD/R) treatment and identified the
potential neuroprotectant human urinary kallidinogenase (HUK;
Gao et al., 2014, 2016). Whether the combination of HUK and
MH could also provide enhancing effects in the HIE adult model
is of interest.
HUK is a tissue kallikrein originally isolated from human
urine that cleaves low molecular weight kininogen to release
bradykinin (Stankowski and Gupta, 2011). HUK can mediate
a complex series of physiological actions through its receptor
signaling pathways, and suppress inflammatory mediators such
as interleukin-1(IL-1), interleukin-6 (IL-6), or TNF-α, selectin
E (ELAM-1), monocyte chemoattractant protein-1 (MCP-1),
and Nuclear Factor-κB (NF-κB; Chen et al., 2010); increase
erythrocyte deformability; prolong the re-calcification time;
lower blood viscosity (Chao and Chao, 2006); and inhibit
platelet aggregation, apoptosis, hypertrophy and fibrosis (Chao
et al., 2010). Accumulated clinical evidence has suggested
that HUK is an effective therapy for acute ischemic stroke
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(Zhang et al., 2012; Li et al., 2015; Miao et al., 2016; Ni
et al., 2017). Recent studies by Han and Li indicated that HUK
promotes post-ischemic angiogenesis and cerebral perfusion
via induction of vascular endothelial growth factor (VEGF)
and activation of bradykinin B1/B2 receptors (BDKRB1/B2),
which further enhanced the expression of VEGF (Han et al.,
2015; Li et al., 2015). In spite of the similar pathophysiological
characteristics of HIE and ischemic stroke, both of which are
caused by low blood and oxygen support and have ischemic
penumbra (Gao et al., 2014), few studies have shown how
HUK functions under HIE insult and whether HUK functions
via mediating VEGF and BDKRB1/B2 receptors. Since VEGF
and doublecortex (DCX) are usually taken as the indices of
angiogenesis and neurogenesis respectively, in this study we
used them as the markers of angiogenesis and neurogenesis
(Couillard-Despres et al., 2005; Garcia et al., 2014; Zhao et al.,
2017). Whether HUK exerts beneficial effects on neurons under
HIE insult and how the combination of HUK and MH are
synergistic or enhance positive effects need to be explored.
Therefore, in the present study, we sought to determine
the following: (1) whether HUK enhances the efficacy of MH
in terms of the rat survival rate, cell death, tight junction
preservation and restoration of neurological function in the
HIE adult rat model; (2) how the expression of VEGF and
BDKRB1/B2 receptors mediates the additional protection of
combined treatment; and (3) whether the combination of HUK
and MH provides enhanced neurogenesis by regulating the
expression of DCX and Ki67 compared to either treatment alone
in HIE adult rats.
MATERIALS AND METHODS
Ethics Statement
The experiments in this study were approved and carried out
in accordance with the Institutional Animal Care and Use
Committee of the Laboratory Animals Center, Southern Medical
University. The protocol was approved by the Institutional
Animal Care and Use Committee (Animal Ethic Approval No:
NYFF-2015-87).We certify that the rats in our study were treated
in accordance with theNational Institutes of Health Guide for the
Care and Use of Laboratory Animals (NIH Publications No. 80-
23) revised 1996 guidelines. We attest that all efforts were made
to minimize the number of animals used and their suffering.
Experimental Design
A total of 144 adult male Wistar rats weighing 300–350 g were
obtained from the Experimental Animal Center of Southern
Medical University. The rats were randomly divided into
five groups: Sham group, which underwent a sham operation;
HIE group, which was subjected to right carotid dissection
followed by hypoxia aspiration (8% O2 with 92% N2 for
3 h; Edwards et al., 2017) to simulate a medium to severe
hypoxia-ischemic encephalopathy neurological severity scores
(NSS; 7–18 scores); HUK group, which was injected with
0.0016 PNAU/100 g HUK (Techpool Bio-pharma, Guangzhou,
China) via the tail vein twice a day in successive 2 days,
starting from 1 h after inducing HIE; MH group, which was
treated with MH (34◦C) for 4.5 h started from 1 h after
inducing HIE; and combined treatment group (HUK+MH),
which was administered with HUK and MH treatment as
preceding methods. The 7-day survival curve and NSS (at days
0, 1, 3, 7) were determined to evaluate the effectiveness of HIE
model. Nine rats in each group were euthanized, the brains
were obtained from rats at 48 h after HIE to do the paraffin
sections and were used for assessment using Nissl, Terminal
deoxynucleotidyl transferase-mediated dUTP nick end-labeling
(TUNEL), immunofluorescent staining and Western Blotting
(Figure 1).
HIE Animal Model
TheWistar adult male rats were anesthetized using 5% isoflurane
and maintained under 1.5% isoflurane anesthesia with 70% N2
and 30% O2, retaining a left femoral artery intubation while
monitoring the rectal temperature. HIE model was set up and
modified following previous studies (Harding et al., 2016; Yang
et al., 2016; Edwards et al., 2017). Briefly, the neck hair was
shaved, and the skin was disinfected first. Then a 15 mm-long
incision was made above the sternum and at the midline
of the neck. Next, the subcutaneous tissue, sternohyoid and
sternocleidomastoid muscles were bluntly separated. When the
right common carotid artery pulse could be seen, we dissociated
the common carotid artery and its two branches of the internal
and external carotid artery, ligated the proximal and distal end
of the internal carotid artery and mutilated the internal carotid
artery in the middle of the two ligations. After confirming no
bleeding, we finally sutured the muscles and skin layer by layer
and disinfected the incision. Afterward, the rats were placed
into a chamber under 8% hypoxia with 92% N2 inhalation for
3 h while maintaining the rectal temperature at 38◦C with a
thermostatic pad. By using Transcranial Doppler (TCD) to verify
that there was no blood flow in the right carotid, the model was
considered to be successfully established.
7-day Survival Curves and Neurological
Severity Scores (NSS)
Seven-day survival curves were made according to the time
and quantity of the rat deaths in each group. Neurologic
deficiency was assessed on the basis of modified NSS assessment.
The NSS evaluation consisted of motor (0–6 scores), sensory
(0–2 scores), reflex (0–4), and balance (0–6 scores) tests, with
the results measured on a scale of 0–18. Score 0 indicates
normal neurologic function, score 1–6 indicates mild deficiency,
score 7–12 indicates moderate deficiency, score 13–18 indicates
severe deficiency (score 18 indicates death). All the mice
subjected to neurological severity assessments were evaluated by
three blinded, trained investigators after inducing HIE (day 0)




Five sections of the dentate gyrus (DG) of right hippocampa
in each rat were detected. In each section, five areas were
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randomly chosen to analyze. TUNEL staining was conducted
using the in situ Cell Death Detection Kit (Roche, 11684795910,
Germany) following the manufacturer’s instructions. Briefly,
we prepared 5 µm thick paraffin sections that were then
immersed in dimethylbenzene I and II (Sigma Aldrich, 296333,
USA) for 15 min and then sequentially dewaxed at 100%,
85%, 75% ethanol (Sigma Aldrich, 49836, USA) and distilled
water for 5 min. Next, we incubated the sections with
diluted protease K (DAKO, Cat. #S3020, USA) at 37◦C for
30 min and with Permeabilization Buffer (Aviva, OOMB00004,
USA) for 20 min at room temperature. Finally, we incubated
the sections with a mixed TUNEL working solution (TdT:
dUTP = 2:29) at 37◦C for 2 h, stained the nuclei with
DAPI (Sigma Aldrich, D9542, USA) at room temperature for
10 min, and sealed the sections with the anti-fluorescence
quenching sealing agent FluoroshieldTM (Sigma Aldrich, F6182,
USA). The prepared sections were photographed with a
NIKON ECLIPSE TI-SR inverted fluorescence microscope
(NIKON, Japan) with a UV excitation wavelength 330–380 nm,
emission wavelength 420 nm (for DAPI); and FITC excitation
465–495 nm, emission 515–555 nm (for TUNEL). The images
were quantified using Image-Pro Plus 6.0 software (Media
Cybernetics Inc., Rockville, MD, USA). The ratio of the
number of TUNEL-positive cells to the number of total nuclei
(DAPI staining) was used to present the intensity of the
TUNEL.
Nissl Staining
Nissl staining was used to observe neurons in the right
hippocampal dentate gyrus (DG) of the insulted hemisphere
with Toluidine Blue Staining Reagent (Sigma Aldrich, 89640,
USA). Briefly, we dewaxed the paraffin sections (as for TUNEL
staining) and stained them with 5% toluidine blue at room
temperature for 10 min. Sections were then soaked in 95%
ethanol (Sigma Aldrich, 49836, USA) for 2min, dimethylbenzene
(Sigma Aldrich, 296333, USA) for 3 min, and sealed with neutral
balsam (Thermo Fisher Scientific Inc., B10100, USA). The Nissl
staining slides were observed using a Nikon microscope (Nikon,
Eclipse Ci-E, Japan). We used neuronal number per mm2 to
measure the survival neurons in Nissl staining. We counted the
number of the neurons in 50× 50µm2 of the initial images, then
calculated the average neuron number per mm2.
Immunofluorescence
Five sections of the DG regions of each hippocampus
were processed for the immunofluorescence detection.
Immunofluorescence detection was conducted at 48 h after
HIE. The paraffin sections were put into dimethylbenzene I
and II (Sigma Aldrich, 296333, USA) for 15 min and then
sequentially dewaxed at 100%, 85%, 75% ethanol (Sigma Aldrich,
49836, USA) and distilled water for 5 min, respectively. For
antigen retrieval, we incubated the sections with citrate buffer
antigen retrieval solution (pH 6.0; Sigma Aldrich, C9999, USA)
in a microwave oven on medium-temperature heat for 8 min
and medium-low-temperature heat for 7 min. After blocking
with a 5% BSA (Sigma Aldrich, B2064, USA) solution for 1 h,
we incubated the sections with primary antibody, anti-VEGF
(a marker of angiogenesis, mainly in vascular endothelial
cells; 1:1000, AbCam, ab46154, UK), anti-doublecortin (a
marker of neurogenesis; 1:1000, AbCam, ab18723, UK), or
anti-Ki67 (a non-specific proliferation of cells; 1:1000, AbCam,
ab15580, UK) antibody for 2 h at room temperature. After
washes, the sections were incubated with secondary antibody,
goat anti-rabbit IgG (Cy3; 1:5000, AbCam, ab6939, UK) or
goat anti-rabbit IgG (FITC; 1:5000, AbCam, ab6717, UK) for
1 h, and then DAPI (Sigma Aldrich, D9542, USA) at room
temperature for 5 min. Finally, the sections were sealed with
the anti-fluorescence quenching sealing agent FluoroshieldTM
(Sigma Aldrich, F6182, USA). The images were collected with
a NIKON Fluorescent Microscope (NIKON, ECLIPSE C1,
Japan) at excitation wavelength 330–380 nm and emission
wavelength 420 nm (blue); FITC excitation 465–495 nm
(green) and emission 515–555 nm; and CY3 excitation
510–560 nm and emission 590 nm (red). The images were
analyzed using Image-pro plus 6.0 (Media Cybernetics Inc.,
Rockville, MD, USA). Five areas were randomly chosen to
analyze in each image. The signal densities of VEGF, DCX
and Ki67 were normalized by the density of the signals of
nuclei.
Western Blotting
For Western Blot analysis, rats were euthanized at 48 h
after HIE and all the right hippocampal tissue was collected
for total protein extraction. The concentration of protein
was determined using the BCA method with the PierceTM
BCA Protein Assay Kit (Thermo Fisher Scientific Inc., 23225,
USA). Thirty-five microgram of protein from each sample was
separated using 4%-12% sodium dodecyl sulfate-polyacrylamide
gel electrophoresis (SDS-PAGE), and then the proteins were
transferred to PVDF membranes (Millipore, IPFL00010, USA).
After blocking with 5% BSA (Sigma Aldrich, B2064, USA)
for 1 h, the membranes were incubated with the primary
antibodies anti-claudin-1 (1:1000, AbCam, ab15098, UK), anti-
Zonula Occludens (anti-ZO-1; 1:1000, AbCam, ab96587, UK),
anti-BDKRB1 (1:1000, Bioss, bs-8675R, USA), anti-BDKRB2
(1:1000, Novus Biologicals, NBP1-46328, USA), anti-cyclin D1
(1:1000, AbCam, ab16667, UK), and anti-GAPDH (1:5000,
AbCam, ab8245, UK) at 4◦C overnight. After three washes, the
membranes were incubated with the secondary antibody Goat
Anti-Rabbit IgG H&L (HRP; 1:5000, AbCam, ab6721, UK) or
antibody Goat Anti-Mouse IgG H&L (HRP; 1:5000, AbCam,
ab6789, UK) at room temperature for 1 h. The bands were
developed using Luminant Western HRP Substrates (Millipore-
Sigma, WBLUM0100, Germany) and exposed using X-ray
photography (Kodak, USA). Gray value (GV) analyses for the
quantification of the bands were performed using Quantity One
Analysis Software (Bio-Rad Laboratories, Quantity One 1-D,
USA). Relative GVs of protein bands were normalized to the
internal control GAPDH.
Statistical Analyses
Continuous data are presented as the mean± standard deviation
(SD). For the survival curve, Log-Rank Test (Kaplan-Meier)
was used. For the repeated measurement data, Mauchly’s test
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FIGURE 1 | Division and treatment of animals. (A) The total profile of the animals which were subjected to the experiment. A total of 144 adult male Wistar rats were
used in this experiment. The rats were randomly divided into five groups: Sham, Hypoxic-ischemic encephalopathy (HIE), Human urinary kallidinogenase (HUK), Mild
hypothermia (MH), and Combination group (n = 24). Before treatment, 24 rats died after HIE was induced, and eight died after treatment, two in HUK group, two in
MH group and four in HIE group. The 7-day survival curve and neurological function assessment (neurological severity scores, NSS) were performed within 7 days
(n = 12). Rats were euthanized and detected at the 48 h after HIE (n = 3 for every detection). (B) The division, treatments and time sequence of the experiment. The
rats were randomly divided into five groups: Sham, HIE, HUK, MH and HUK + MH (combination) group. Rats in Sham group accepted sham operation and no
treatments. Rats in HIE received operation with no treatment; rats in HUK were injected with 0.0016 PNAU/100 g HUK via the tail vein twice a day in successive
2 days, starting from 1 h after inducing HIE; rats in the MH group were treated with MH (34◦C) for 4.5 h starting at 1 h after inducing HIE; and rats in the combined
treatment group (HUK+MH) accepted HUK and MH treatment as prescribed. The 7-day survival curve and neurological function assessments (at day 0, 1, 3, 7) were
performed. Terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling (TUNEL), Nissl, immunofluorescent staining and Western Blot were performed at
the 48-h time point after HIE.
of sphericity was used to determine whether they fit the
spherical distribution. When the data did not fit the spherical
distribution, the MANOVA test was made first, followed by
LSD test being used to compare multiple groups. For the
two-factor design, two-way ANOVA was used to analyze the
interaction of two factors, and the main or single effect of each
factor was analyzed by a General Linear Model. For multiple
comparisons, analyses were conducted by two-way ANOVA
followed by Tukey’s test. The significance level was set at
P< 0.05, two-tailed. All statistical analyses were performed using
IBM SPSS Version 20 (SPSS Statistics V24, IBM Corporation,
Armonk, NY, USA).
RESULTS
The Combination of HUK and MH
Improved the Survival Curve and Increased
the Neurological Function
The survival curve of HIE group was the lowest in the survival
curve chart, 4 out of 12 rats died, and three were at day 1 and one
at day 4 (Figure 2A). HUK or MH ended with 2 deaths among
12 rats but had no difference of survival with the HIE group (Log-
Rank Test (Kaplan-Meier), χ2 = 0.848, P = 0.357, Figure 2A).
The best survival (0 out of 12 died, Figure 2A) was noted when
HUK was combined with MH, which was the same as the Sham
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FIGURE 2 | Survival curves and the analysis of NSS. (A) 7-day survival curves: the 7-day survival curves were created according to the deaths in each group at
different time points (n = 12). The survival curve of HIE group was the lowest in the survival curve chart, 4 out of 12 died, three were at day 1 and one at day 4. HUK
or MH ended with two deaths of 12. The best survival curve (0 out of 12 died) was noted when HUK was combined with MH, which was the same as the Sham
Group (0 out of 12 died). The survival curves of HUK and MH groups have no difference with that of the HIE group (Log-Rank Test (Kaplan-Meier), χ2 = 0.848,
P = 0.357), but the survival curve of combination is better than that of the HIE group (Log-Rank Test (Kaplan-Meier), χ2 = 4.615, ∗P = 0.032). (B) The analysis of
NSS scores: Mauchly’s test of sphericity shows the NSS scores does not fit the spherical distribution (Mauchly’s test of sphericity, χ2 = 85.722, ∗∗∗P < 0.001). There
is an interaction between the different treatments and the time points (MANOVA, F = 6.990, ∗∗∗P < 0.001). (C) NSS analyses in groups: among the Sham, HIE, HUK,
MH and combination of HUK and MH groups (n = 12), NSS assessments were carried out at day 0, day 1, day 3 and day 7. The bar shows the NSS score of every
group. The NSS scores are statistically different at different time points (MANOVA, F = 61.585, ∗∗∗P < 0.001). At day 0, there is no statistical difference among
different treatments (MANOVA, Fday 0 = 0.006, Pday 0 = 0.999). At day 1 and day 3, only combination, not HUK or MH alone reduced the NSS scores after HIE
(MANOVA, LSD test, ∗Pday 1: Combi-HIE = 0.013, ∗Pday 3: Combi-HIE = 0.049). At day 7, the combination reduces the NSS scores compared to HIE (MANOVA, LSD test,
∗∗PCombi-HIE = 0.002), and better than HUK or MH (MANOVA, LSD test, ∗PCombi-HUK = 0.043, ∗PCombi-MH = 0.026). But neither HUK nor MH were different to the HIE
group (MANOVA, LSD test, PHUK-HIE = 0.233, PMH-HIE = 0.331). ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001.
Group and better than the HIE group (0 out of 12 died, Log-Rank
Test (Kaplan-Meier), χ2 = 4.615, ∗P = 0.032, Figure 2A).
For NSS analysis, the Mauchly’s test of sphericity was
used to confirm that the NSS did not fit the spherical
distribution (Mauchly’s test of sphericity, χ2 = 85.722,
P < 0.001). There is an interaction between the different
treatments and the time points (MANOVA, F = 6.990,
P < 0.001, Figure 2B). Among the Sham, HIE, HUK, MH
and combination of HUK and MH groups (n = 12), the
NSS scores are statistically different (MANOVA, F = 61.585,
∗∗∗P < 0.001). At day 0, there is no statistical difference among
different treatments (MANOVA, LSD test, Fday 0 = 0.006,
Pday 0 = 0.999, Figure 2C). At day 1 and day 3, only the
combination of HUK and MH, but not HUK or MH
alone reduced the NSS scores after HIE (Combinationday 1:
8.750 ± 1.138, HIEday1: 11.750 ± 3.841, MANOVA,
LSD test, ∗Pday 1: Combi-HIE = 0.013; Combinationday 3:
3.667 ± 1.073, HIEday 3: 7.833 ± 6.221, MANOVA, LSD
test, ∗Pday 3:Combi-HIE = 0.049, Figure 2C). At day 7, there are
statistical difference among different treatments (MANOVA,
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FIGURE 3 | Nissl and TUNEL Staining of the right hippocampal region. (A) Nissl staining in hippocampus dentate gyrus (DG). Representative images of Niss-staining
in the hippocampus DG are shown at 200× (the left images, Scale bar = 50 µm) and 400× magnification (the right images, Scale bar = 20 µm). Nissl bodies are
deep blue and the nuclei are light blue. The most normal neurons are seen in the combination group compared to the HUK, MH and HIE groups (n = 3). (B) The
Quantification of Nissl staining in hippocampus dentate gyrus. Each bar shows the average cell number per mm2 of each group. HUK had an interaction with MH
(two-way ANOVA, F = 31.824, ∗∗∗P < 0.001). HUK or MH treatments attenuated HIE-induced neuronal decline (HUK: 14320.000 ± 1797.776 cells/mm2, MH:
12160.000 ± 1252.198 cells/mm2, HIE: 8000.000 ± 1414.214 cells/mm2, two-way ANOVA, Tukey’s Test, ∗∗∗PHUK-HIE < 0.001, ∗∗PMH-HIE = 0.003). The
combination had a better effect on the survival of neurons, better than HUK or MH alone (Combination: 17200.000 ± 1624.808 cells/mm2, ∗∗∗PCombi-HIE < 0.001,
∗PCombi-HUK = 0.041, ∗∗∗PCombi-MH < 0.001). (C) TUNEL staining in hippocampus DG. TUNEL positive cells (n = 3), including cells with apoptosis and necrosis, are
green and the nuclei of cells are blue. The merged images were made by TUNEL and DAPI staining. The magnification is 400×. Scale bar = 20 µm. (D) The
Quantification of TUNEL. The images were quantified and presented by the ratio of the number of TUNEL positive cells to the number of nuclei (DAPI). Each bar
shows the percentage of the average positive ratio for each group. HUK synergistically interacts with MH on TUNEL (two-way ANOVA, F = 104.600, ∗∗∗P < 0.001).
HUK or MH alone reduces the TUNEL-labeled cells compared to HIE (two-way ANOVA-Tukey’s test, ∗∗∗PHUK-HIE < 0.001, ∗∗∗PMH-HIE < 0.001), and the combination
is better than MH (two-way ANOVA-Tukey’s test, ∗∗PCombi-HUK = 0.005, ∗∗∗PCombi-MH < 0.001). ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001.
Fday 7 = 3.828, ∗Pday 7 = 0.016, Figure 2C). The combination
reduces the NSS scores compared to HIE (Combination:
1.167 ± 1.115, HIE: 8.417 ± 7.128, MANOVA, LSD test,
∗∗PCombi-HIE = 0.002, Figure 2C), and better than HUK or MH
(HUK: 5.750 ± 5.786, MH: 6.250 ± 5.562, MANOVA, LSD
test, ∗PCombi-HUK = 0.043, ∗PCombi-MH = 0.026, Figure 2C).
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However, neither HUK nor MH were different to the HIE group
(MANOVA, LSD test, PHUK-HIE = 0.233, PMH-HIE = 0.331,
Figure 2C).
HUK Increased the Survival Neurons, and
the Combination of HUK and MH Provided
More Neuroprotection
We used neuronal number per mm2 to measure the survival
neurons in Nissl staining. HUK had an interaction with
MH as shown by the Nissl staining results (two-way
ANOVA, F = 31.824, P < 0.001). In the sham group,
the survival neurons in the hippocampal DG were the
highest (24080.000 ± 2287.357 cells/mm2, Figures 3A,B).
HUK or MH treatments attenuated HIE-induced neuronal
number decline (HUK: 14320.000 ± 1797.776 cells/mm2,
MH: 12160.000 ± 1252.198 cells/mm2, HIE:
8000.000 ± 1414.214 cells/mm2, two-way ANOVA, Tukey’s
Test, ∗∗∗PHUK-HIE < 0.001, ∗∗PMH-HIE = 0.003, Figures 3A,B).
The combination had a better effect on the survival of
neurons, better than HUK or MH alone (Combination:
17200.000 ± 1624.808 cells/mm2, ∗∗∗PCombi-HIE < 0.001,
∗PCombi-HUK = 0.041, ∗∗∗PCombi-MH < 0.001, Figures 3A,B).
HUK synergistically interacted with MH as shown by the
TUNEL staining results (two-way ANOVA, F = 104.600,
P < 0.001). Accordingly, HIE induced apoptosis from
2.772 ± 1.58% (Sham group) to 48.480 ± 5.532%, as measured
by TUNEL staining. HUK or MH alone induced a significant
reduction in apoptosis (green; HUK: 10.230 ± 3.554%, MH:
29.600 ± 3.003, Figures 3C,D) compared to the HIE group
(two-way ANOVA, Tukey’s test, ∗∗∗PHUK-HIE < 0.001,
∗∗∗PMH-HIE < 0.001, Figures 3C,D), and had a further
protective effect when combined (1.229 ± 0.603%),
better than HUK or MH alone (two-way ANOVA,
Tukey’s test, ∗∗PCombi-HUK = 0.005, ∗∗∗PCombi-MH < 0.001,
Figures 3C,D).
HUK Upregulated VEGF-Labeled Cells,
Tight Junctions and BDKRB1/B2, and the
Combination of HUK and MH Enhanced
the Effects of HUK or MH Alone
Since HUK or combined treatment can prevent neural apoptosis,
we investigated if HUK, MH or the combination can promote
angiogenesis since vascular endothelial cells constitute of the
critical part of BBB construction. The neuroprotective effect
of HUK has been shown to be correlated with the BDKRB1
and the BDKRB2 (Han et al., 2015). We also examined if
the protein levels of BDKRB1 and BDKRB2 were altered in
the rat right hippocampus. Results showed that HUK had
a synergistic effect with MH on VEGF-labeled cells (two-
way ANOVA, F = 158.140, P < 0.001, Figure 4B). The
VEGF-labeled cells were detected by anti-VEGF antibody
immunofluorescent staining (VEGF, a marker of angiogenesis,
mainly expressed in vascular endothelial cells, Beck and
Plate, 2009). The ratios of the signal of VEGF-positive
cell to cell nuclei (DAPI staining) increased in the HUK
(0.063 ± 0.002) and MH groups (0.048 ± 0.004) compared
to the HIE group (0.022 ± 0.002; two-way ANOVA, Tukey’s
test, ∗∗∗PHUK-HIE < 0.001, ∗∗∗PMH-HIE < 0.001, Figures 4A,C).
In the combined treatment group (0.098 ± 0.007), the ratio
was higher than the other treatment groups (two-way ANOVA,
Tukey’s test, ∗∗∗PCombi-HUK < 0.001, ∗∗∗PCombi-MH < 0.001,
Figures 4A,C).
Furthermore, HUK synergistically interacts with MH on
BDKRB1 (two-way ANOVA, F = 21.053, P = 0.001) and
BDKRB2 (two-way ANOVA, F = 38.759, P < 0.001). HUK
or MH obviously ameliorated the HIE-induced decrease
in BDKRB1 (HUK: 0.463 ± 0.066, MH: 0.492 ± 0.035 vs.
HIE: 0.291 ± 0.033, two-way ANOVA-Tukey’s test,
∗PHUK-HIE = 0.036, ∗PMH-HIE = 0.016, Figures 4D,E) and
BDKRB2 proteins (HUK: 0.953 ± 0.050, MH: 0.893 ± 0.063 vs.
HIE: 0.529 ± 0.124, two-way ANOVA-Tukey’s test,
∗PHUK-HIE = 0.004, ∗PMH-HIE = 0.012, Figures 4D,E). The
combination of HUK and MH further markedly improved
the HIE-induced decrease in BDKRB1 (0.679 ± 0.088)
and BDKRB2 (1.355 ± 0.116, two-way ANOVA-Tukey’s
test, B1 and B2: ∗∗∗PCombi-HIE < 0.001, Figures 4D,E),
better than either HUK or MH (two-way ANOVA-Tukey’s
test, B1: ∗PCombi-HUK = 0.010, ∗PCombi-MH = 0.024; B2:
∗∗PCombi-HUK = 0.007, ∗∗ PCombi-MH = 0.003, Figures 4D,E).
We also found the same trends in the tight junction
associated proteins claudin-1 and ZO-1 (Figure 4F). HUK
synergistically interacted with MH to affect claudin-1 and ZO-1
(two-way ANOVA, FClaudin-1 = 395.489, PClaudin-1 < 0.001;
FZO−1 = 107.890, PZO−1 < 0.001, Figures 4F,G). Claudin-1 and
ZO-1, as measured by Western Blotting, obviously increased in
the HUK (claudin-1: 0.479 ± 0.038, two-way ANOVA, Tukey’s
test, ∗∗∗PHUK-HIE < 0.001; ZO-1: 0.164 ± 0.027, two-way
ANOVA-Tukey’s test, ∗∗∗PHUK-HIE < 0.001, Figures 4F,G)
and MH (claudin-1: 0.261 ± 0.002, two-way ANOVA,
Tukey’s test, ∗PMH-HIE = 0.012; ZO-1: 0.099 ± 0.016,
∗PMH-HIE = 0.012, Figures 4F,G) groups and were the
highest in the combination group (claudin-1: 0.846 ± 0.038,
two-way ANOVA, Tukey’s test, ∗∗∗PCombi-HIE < 0.001; ZO-1:
0.285 ± 0.018, ∗∗∗PCombi-HIE < 0.001, Figures 4F,G) after
HIE (claudin-1: 0.140 ± 0.006, ZO-1: 0.036 ± 0.002). The
claudin-1 and ZO-1 in combination group were higher
than HUK or HUK alone (two-way ANOVA-Tukey’s test,
Claudin-1: ∗∗∗PCombi-HUK < 0.001, ∗∗∗PCombi-MH < 0.001;
ZO-1: ∗∗∗PCombi-HUK < 0.001, ∗∗∗PCombi-MH < 0.001,
Figures 4F,G). These data indicated that the neuroprotective
effects of the combination came from the synergistic effects
of HUK and MH on VEGF-labeled cells, claudin-1 and
ZO-1 and were at least partly associated with BDKRB1 and
BDKRB2.
HUK Increased DCX-Labeled Cells and
Cyclin D1, and the Combination of HUK
and MH Enhanced These Effects
Given the enhancement effect of HUK and the combined
treatment on angiogenesis, we further examined whether
HUK and the combined treatment have a positive effect on
neuronal regeneration (as marked by doublecortin, DCX)
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FIGURE 4 | Comparison of vascular endothelial growth factor (VEGF)-labeled cells and Bradykinin B2/B1 receptor (BDKRB1/B2), Claudin-1 and Zonula Occludens
(ZO)-1 proteins. (A) VEGF-labeled cells (n = 3): The VEGF-labeled cells are green and the nuclei are blue dyed by DAPI. The merged images were created by both
anti-VEGF staining and DAPI staining. The magnification is 400×. Scale bar = 20 µm. (B) The interaction analysis of HUK and MH. HUK synergistically interacts with
MH on VEGF-labeled cells (two-way ANOVA, F = 158.140, ∗∗∗P < 0.001). (C) The quantification of VEGF. The images of VEGF-staining were quantified by the signal
of VEGF normalized by the signal of nuclei. Each bar shows the average ratio of each group. HUK or MH alone increases the VEGF-staining compared with HIE
(two-way ANOVA-Tukey’s test, ∗∗∗PHUK-HIE < 0.001, ∗∗∗PMH-HIE < 0.001), and the combination increases it to the peak (two-way ANOVA-Tukey’s test,
∗∗∗PCombi-HIE < 0.001), better than either of them alone (two-way ANOVA-Tukey’s test, ∗∗∗PCombi-HUK < 0.001, ∗∗∗PCombi-MH < 0.001). ∗P < 0.05, ∗∗P < 0.01,
∗∗∗P < 0.001. (D) BDKRB1 and BDKRB2 expression lever. The detection of the level of BDKRB1 and BDKRB2 proteins (n = 3). GAPDH was used as an internal
control protein (n = 3). (E) The quantification of BDKRB1 and BDKRB2. Each bar represents the ratio of the Gray value (GV) of each protein band normalized by the
internal control protein GAPDH. HUK synergistically interacts with MH on BDKRB1 (two-way ANOVA, F = 21.053, P = 0.001) and BDKRB2 (two-way ANOVA,
F = 38.759, P < 0.001). HUK or MH alone rescues the decrease in BDKRB1 caused by HIE (two-way ANOVA-Tukey’s test, ∗PHUK-HIE = 0.036, ∗PMH-HIE = 0.016),
and the combination improves BDKRB1 compared to HIE (two-way ANOVA-Tukey’s test, ∗∗∗PCombi-HIE < 0.001) better than either HUK or MH (two-way
ANOVA-Tukey’s test, ∗PCombi-HUK = 0.010, ∗PCombi-MH = 0.024). HUK or MH alone increases the BDKRB2 compared to HIE (two-way ANOVA-Tukey’s test,
∗∗PHUK-HIE = 0.004, ∗PMH-HIE = 0.012), and the combination gives the highest value (two-way ANOVA-Tukey’s test, ∗∗∗PCombi-HIE < 0.001), better than either HUK or
MH (two-way ANOVA-Tukey’s test, ∗∗PCombi-HUK = 0.007, ∗∗PCombi-MH = 0.003). ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001. (F) The expression of claudin-1 and ZO-1. The
claudin-1 and ZO-1 proteins were measured by western blotting (n = 3). GAPDH was used as an internal control protein (n = 3). (G) The quantification of claudin-1
and ZO-1. Each bar shows the ratio of the GV of each protein band normalized to the internal control protein GAPDH. HUK and MH have synergistic interactions on
claudin-1 and ZO-1 (two-way ANOVA, Fclaudin-1 = 395.489, ∗∗∗PClaudin-1 < 0.001; FZO−1 = 107.890, ∗∗∗PZO−1 < 0.001). HUK or MH increases the expression of
claudin-1 (two-way ANOVA-Tukey’s test, ∗∗∗PHUK-HIE < 0.001, ∗PMH-HIE = 0.012) and ZO-1 (two-way ANOVA-Tukey’s test, ∗∗∗PHUK-HIE < 0.001, ∗PMH-HIE = 0.012),
and combination increases claudin-1 and ZO-1 to the peak (two-way ANOVA-Tukey’s test, claudin-1: ∗∗∗PCombi-HIE < 0.001, ZO-1: ∗∗∗PCombi-HIE < 0.001), better
than either of them alone (two-way ANOVA-Tukey’s test, claudin-1: ∗∗∗PCombi-HUK < 0.001, ∗∗∗PCombi-MH < 0.001; ZO-1: ∗∗∗PCombi-HUK < 0.001,
∗∗∗PCombi-MH < 0.001). ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001.
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FIGURE 5 | Comparison of Doublecortin (DCX)-labeled cells and the protein level of cyclin D1. (A) DCX staining (n = 3). The DCX-labeled cells are green and the
nuclei are blue dyed by DAPI staining. The merged images were created by anti-DCX staining and DAPI staining. The magnification is 400×. Scale bar = 20 µm.
(B) The interaction analysis of HUK and MH on DCX-staining. The HUK interacts with MH on DCX-staining (F = 404.200, ∗∗∗P < 0.001). (C) The quantification of the
DCX-staining. The images of DCX-staining were quantified by the signal of DCX normalized by the signal of nuclei. Each bar shows the average ratio of each group.
Either HUK or MH increases the DCX-labeled cells after HIE (two-way ANOVA-Tukey’s test, ∗∗∗PHUK-HIE < 0.001, ∗∗∗PMH-HIE < 0.001). The combination increases it
to the peak (two-way ANOVA-Tukey’s test, ∗∗∗PCombi-HIE < 0.001), better than HUK or MH alone (two-way ANOVA-Tukey’s test, ∗∗∗PCombi-HUK < 0.001,
∗∗∗PCombi-MH < 0.001). ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001. (D) The expression of cyclin D1. The expression of cyclin D1 was measured by western blotting (n = 3).
GAPDH was used as an internal control protein (n = 3). (E) The quantification of cyclin D1. Each bar represents the ratio of the GV of each protein band normalized to
the internal control protein GAPDH. HUK additively interacts with MH on cyclin D1 (two-way ANOVA, F = 221.542, ∗∗∗P < 0.001). HUK or MH alone increases the
cyclin D1 level after HIE (two-way ANOVA-Tukey’s test, ∗∗∗PHUK-HIE < 0.001, ∗∗∗PMH-HIE < 0.001). The combination increases the cyclin D1 level to the highest value
(two-way ANOVA- Tukey’s Test, ∗∗∗PCombi-HIE < 0.001), higher than HUK or MH alone (two-way ANOVA-Tukey’s test, ∗∗∗PCombi-HUK = 0.001, ∗∗∗PCombi-MH < 0.001).
∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001.
and cyclin D1, a regulator of the G1/S phase transition
(Frade and Ovejero-Benito, 2015). Immunofluorescent
staining showed an increase in the DCX-marked positive
cells of the HUK or MH groups (HUK: 2.139 ± 0.036, MH:
1.725 ± 0.094 vs. HIE: 0.067 ± 0.004, two-way ANOVA,
Tukey’s test, ∗∗∗PHUK-HIE < 0.001, ∗∗∗PMH-HIE < 0.001,
Figures 5A,C). Although HUK had an additive interaction with
MH on DCX-labeled positive cells (two-way ANOVA-Tukey’s
test, F = 404.200, P < 0.001, Figure 5B), a stronger effect
was observed in the combination group (2.926 ± 0.163,
two-way ANOVA, Tukey’s test, ∗∗∗PCombi-HIE < 0.001,
Figures 5A,C) than HUK or MH alone (two-way ANOVA,
Tukey’s test, ∗∗∗PCombi-HUK < 0.001, ∗∗∗PCombi-MH < 0.001,
Figures 5A,C).
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FIGURE 6 | Comparison of the Ki67-labeled Cells. (A) Ki67 staining (n = 3). The Ki67-labeled cells are red and the nuclei are blue, as shown by DAPI staining. The
merged images were created from the results of anti-Ki67 staining and DAPI staining. The magnification is 400×. Scale bar = 20 µm. (B) Interaction analysis of HUK
and MH on Ki67 staining. HUK additively interacts with MH on Ki67 (two-way ANOVA, F = 178.700, ∗∗∗P < 0.001). (C) The quantification of Ki67 staining. The
images of Ki67-staining were quantified by the signal of Ki67 normalized by the signal of nuclei. Each bar shows the average ratio of each group. HUK or MH
increases the Ki67-labeled cells (two-way ANOVA–Tukey’s test, ∗∗∗PHUK-HIE < 0.001, ∗∗∗PMH-HIE < 0.001). The combination increases the Ki67-positive cells to the
highest (two-way ANOVA-Tukey’s test, ∗∗∗PCombi-HIE < 0.001), higher than HUK or MH alone (two-way ANOVA-Tukey’s test, ∗∗∗PCombi-HUK < 0.001,
∗∗∗PCombi-MH < 0.001). ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001.
Western blotting showed that HUK or MH attenuated the
HIE-induced decrease in cyclin D1 (HUK: 0.688 ± 0.049,
MH: 0.528 ± 0.030 vs. HIE: 0.197 ± 0.014, two-way ANOVA-
Tukey’s test, ∗∗∗PHUK-HIE < 0.001, ∗∗∗PMH-HIE < 0.001,
Figures 5D,E). HUK still had an additive interaction with MH
on cyclin D1 (two-way ANOVA, F = 221.542, ∗∗∗P < 0.001)
and an enhanced protective effect was also seen for the
combination treatment (2.926 ± 0.163, two-way ANOVA-
Tukey’s test, ∗∗∗PCombi-HIE < 0.001, Figures 5D,E), higher
than HUK or MH alone (two-way ANOVA-Tukey’s test,
∗∗∗PCombi-HUK < 0.001, ∗∗∗PCombi-MH < 0.001, Figures 5D,E),
suggesting that the combination at least partly regulates
the cell cycle to promote neurogenesis in HIE adult
rats.
HUK Increased Ki67-Labeled Cells, and the
Combination of HUK and MH Enhanced
the Effect
We used Ki67 staining to confirm the non-specific proliferation
of all cells. Ki67 labels the G and S phase cells and highly
expresses in proliferative cells. The results showed that HUK
additively interacts with MH on Ki67-labeled cells (two-way
ANOVA, F = 178.700, P < 0.001, Figure 6B). The signal
of Ki67 staining normalized by the signal of DAPI had
no significant change after HIE induced (0.005 ± 0.001),
compared with sham group (0.006 ± 0.001). HUK or MH
obviously increased the Ki67 to 0.039 ± 0.008 (two-way
ANOVA, Tukey’s test, ∗∗∗PHUK-HIE < 0.001, Figures 6A,C)
and (0.053 ± 0.004, two-way ANOVA, Tukey’s test,
∗∗∗PMH-HIE < 0.001, Figures 6A,C). Moreover, the combination
increased the Ki67 to the highest level 0.086 ± 0.002 (two-way
ANOVA, Tukey’s test, ∗∗∗PCombi-HIE < 0.001, Figures 6A,C),
better than either HUK or MH alone (two-way ANOVA,
Tukey’s test, ∗∗∗PCombi-HUK < 0.001, ∗∗∗PCombi-MH < 0.001,
Figures 6A,C).
DISCUSSION
This study shows that HUK may be a potential neuroprotectant,
functioning to induce angiogenesis and promote neuronal
regeneration in an adult HIE rodent model. In this study, we
investigated the effects of MH and HUK in the HIE model
and noted four principal findings. First, we observed that the
combination of HUK and MH rescued all adult HIE rats from
death and profoundly improved neurological dysfunction at
days 7. Second, MH significantly attenuated the tight-junction
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disruptions and increased the expressions of VEGF, BDKR
B1/2, cyclin D1, Ki67 and doublecortin (DCX). Third, HUK
enhanced these neuroprotective effects of MH. Lastly, the
combination of MH and HUK may have their angiogenesis and
neuronal regeneration effects at least partially via upregulating
the expression of BDKR B1/2, and doublecortin (DCX). To
our knowledge, this is the first study to explore the neuro-
pathogenesis of combined MH and HUK therapy in the HIE
model.
Although several lines of evidence demonstrate that HUK
and MH may play important roles against ischemic stroke
(Chen et al., 2010; Gao et al., 2014; Han et al., 2015), the
efficacy of either single or combined treatment in HIE still
needs to be explored and the neuro-pathogeneses involved in the
neuroprotection need to be confirmed. From day 1 to 7, although
neither HUK nor MH attenuated the neurological deficit, their
combination profoundly ameliorated behavioral impairment,
strongly suggesting that HUK enhanced the beneficial effect
of MH. The neurological behavioral improvement continued
for all observations on days 1, 3 and 7 after HIE, indicating
that a short period of administration of exogenous HUK
can persistently improve neurological dysfunction over a
relatively long time. This result is similar to Han’s study
showing that HUK could improve neurological dysfunction
in ischemic stroke rats (Han et al., 2015). We found that
HUK or MH prevented neurons from undergoing necrosis and
apoptosis, while this combination led to a more pronounced
neuronal survival, indicating that this combination of HUK
and MH could provide more effective neuroprotection and
this combination enhanced the neuroprotective effects of either
alone.
It has been well documented that ZO-1 (Tight junction
protein-1) and claudin-1, a group of integral membrane proteins,
are closely associated with BBB integrity, representing one mode
of cell-to-cell adhesion in endothelial cell sheets and responsible
for the barrier function of brain vessels (Luissint et al., 2012;
Ren et al., 2015; Li et al., 2016; Zanotto et al., 2017; Bhargavan
and Kanmogne, 2018). Dysfunction of BBB mechanisms is well
established after ischemia (Fernández-López et al., 2012; Oakley
and Tharakan, 2014; Liu et al., 2017); however, we know less
about how tight junctions respond to HIE insult and if HUK/MH
influences the tight junctions under HIE stimulus. Our study
showed that the expression of ZO-1 and claudin-1 in the cortex
were significantly downregulated on day 2 following HIE insult
and that MH attenuated this downregulation. This finding
is consistent with previous studies indicating a similar BBB
disruption with changes in tight-junction proteins in neonatal
HIE and ischemic stroke (Ek et al., 2015; Shi et al., 2017). Our
result strongly indicated that HIE insult may significantly disrupt
the integrity of the BBB, while HUK or MH prevent the injury
of endothelial cells and decrease the loss of tight junctions. In
addition, the combination of HUK and MH exerted a much
larger benefit on tight junction expression in HIE rats, and this
attenuation of the destruction of tight junctions may contribute
to the protective effects of HUK and MH on BBB integrity.
These findings (Figures 4A–C,F,G) suggest that the synergistic
neuroprotective effects of HUK and MH on BBB may at least
partially result from endothelial cell stabilization and decreases
in the loss of tight junctions.
Accumulated evidence has shown that HUK may be
associated with angiogenesis in ischemic stroke (Ek et al., 2015).
We propose that in HIE rats, HUK may exert neuroprotection
partially via modulating angiogenesis and regeneration. To
investigate this hypothesis, we detected VEGF, BDKR B1/B2,
Doublecortin (DCX), Cyclin D and Antigen Ki-67 (Ki-67)
along the hippocampus by immunohistochemistry and western
blotting.
In the current study, the increased VEGF at day 2 following
HIE along the hippocampus suggests that angiogenesis may
occur after HIE onset. This result is similar to previous studies
(Schoch et al., 2002; Han et al., 2015; Shi et al., 2017), indicating
that hypoxic insult may lead to a significant increase in the
levels of VEGF in mouse brain that correlated with the hypoxic
stimulus. This upregulated VEGF expression induced by HIE
in the brain may play both neurotoxic and neuroprotective
roles: (1) leading to vasogenic edema and the leakage
of blood-borne substances into the brain parenchyma and
increased BBB permeability; and (2) stimulating and sustaining
regeneration and neovascularization. The neuroprotective effect
of upregulated VEGF occurs from several hours to several
weeks following hypoxic-ischemia (Sun and Guo, 2005; Kaur
and Ling, 2009; Baburamani et al., 2012). Since VEGF has
been well documented as playing a role in angiogenesis
(Doeppner et al., 2017; Zhao et al., 2017; Zou et al., 2017),
our finding demonstrates that either HUK or MH promotes
angiogenesis, but the combination gave the highest value.
In addition, we also noted the downregulated expression of
the BDKRB1/2 after HIE insult, while HUK, MH and the
combination restored the downregulation of BDKRB1/2. It
has been documented that the activation of BDKRB1/2 is
involved in the angiogenesis process (Spinetti et al., 2011;
Mousa et al., 2014). Our observation that HUK mediated
angiogenesis following HIE insult is similar to previous studies
(Han et al., 2015; Li et al., 2015). Xu’s group found that
in ischemic experimental models and stroke patients, HUK
promoted post-ischemic angiogenesis and cerebral perfusion
via increasing vessel density, enhancing VEGF and apelin/APJ
expression, and inducing ERK1/2 phosphorylation (Han et al.,
2015; Li et al., 2015). Taken together, these data strongly indicate
that the BDKRB1/B2 receptors were involved in the angiogenetic
effect of HUK in HIE rats, and HUK may promote angiogenesis
in HIE stimulus via upregulating the expression of VEGF and
BDKRB1/2.
To further explore whether the combined effects of HUK
and MH on the HIE insult were associated with neurogenesis or
regeneration of all kinds of cells, DCX, which is an important
predictor of neurogenesis, and cyclin D1 and Ki-67, which are
predictors of non-specific regeneration, were evaluated. Cyclin
D1 is a member of the cyclin protein family, plays essential
roles in regulating cell cycle progression and proliferation and
is usually recognized as a biomarker of regeneration of cells
(Bouchard-Cannon et al., 2013; Cheyuo et al., 2015). Ki67 labels
the G and S phase cells and highly expresses in proliferative
cells (Yang et al., 2018). In the current study, our observation
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that cyclin D1 and Ki67 decreased with adult HIE insult implies
that hypoxic-ischemic cells undergo death and regeneration is
markedly reduced. Impressively, either MH or HUK treatment
significantly reversed the HIE-induced downregulation of cyclin
D1 andKi67, strongly indicating thatMH (Yenari andHan, 2013;
Wood et al., 2016) or HUK following HIE onset could enhance
regeneration by positively influencing regeneration of neurons
or other cell. The mechanisms of MH or HUK enhancing
regenerative properties in the current study could be explained,
in part, by its effect on reducing apoptosis (Figure 3) and
enhancing angiogenesis in a crucial time window, as indicated
by the upregulation of VEGF. This MH-induced neurogenesis in
the current work is consistent with Silasi and Colbourne’s (2011)
study, indicating that hypothermia promoted CA neurogenesis
and cell regeneration in global ischemia. To further identify
the effects of MH and HUK on neurogenesis, we examined
the expression of doublecortin (DCX), a candidate marker for
adult neurogenesis, by immunohistochemical staining in the
hippocampus, and observed a change similar to cyclin D1
(Figures 5D,E). More interestingly, our study showed that the
combination of MH and HUK led to more pronounced increase
in the expression of DCX when compared to MH or HUK alone,
indicating greater efficacies of neurogenesis. To our knowledge,
this is the first study showing that HUK exerts neurogenesis
functions by regulating DCX in adult HIE insult.
In addition to mediating angiogenesis and promoting
proliferation, other mechanisms, like inhibiting vasodilation,
suppressing inflammation and activating the innate immune
response, are found to be involved in HUK’s effects against
ischemia (Ponticelli and Meroni, 2009; Chen et al., 2010;
Sharma and Narayanan, 2014). In addition, Chen et al. (2010)
found that HUK not only suppresses cerebral inflammation
and downregulates NF-κB, but also activates the MAPK/ERK
pathway in an experimental ischemic model. Whether those
molecular mechanisms play important roles in HIE insult needs
to be further explored.
In summary, for the first time, this study demonstrates the
beneficial effects of a combination therapy of MH and HUK for
treating adult HIE rats. The combination of MH and HUK was
associated with improvement in functional recovery, combined
cellular neuroprotection, attenuation of tight junction reduction,
promotion of angiogenesis and regeneration in HIE rats. This
finding is clinically meaningful because it strongly implies that
an early combination of MH and HUK may correlate with
improved outcomes and reduced mortality in patients with
HIE. These data support the strategy of combining MH with
pharmacological HUK to increase the clinical feasibility, efficacy
and safety of the treatment of HIE patients. The combined
treatment could represent a promising approach to create more
effective and safer hypothermia therapies for patients with brain
injuries.
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